drugset / Trial / NCT05482451
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to examine the anticancer activity of the combination therapy with all-trans retinoic acid and nivolumab in patients with chemotherapy-refractory advanced or metastatic pancreatic adenocarcinoma.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2025-02-28
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Tretinoin | Small molecule | 150 mg/m2 | — |
Indications
No indication recorded.